Gilead Sciences announced its third quarter 2026 financial results, reporting a 13% increase in total product sales to $8.3 billion driven by growth in HIV and oncology products. The company also raised its full-year 2026 base business revenue guidance for the year, bringing total increases to $1.6 billion since the start of the year.
Total third quarter 2026 product sales increased 13% year-over-year to $8.3 billion.
GAAP diluted earnings per share was $1.94 for the third quarter of 2026 compared to $2.43 in the prior year period.
Full-year 2026 product sales guidance was raised to a range of $31.0 billion to $31.3 billion.
As of September 30, 2026, cash, cash equivalents and marketable debt securities totaled $6.4 billion.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Gilead Sciences's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$29.44B
+2.4%
$6.78
+1684.2%
28.9%
FY2024
$28.75B
+6.0%
$0.38
-91.6%
1.7%
FY2023
$27.12B
-0.6%
$4.50
+23.6%
20.9%
FY2022
$27.28B
-0.1%
$3.64
-26.2%
16.8%
FY2021
$27.30B
+10.6%
$4.93
+4830.0%
22.8%
Frequently asked questions
When is Gilead Sciences's next earnings date?
Gilead Sciences has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Gilead Sciences earn last quarter?
For the quarter ended Sep 2026, Gilead Sciences reported diluted EPS of $1.94 (-20.2% year over year) on revenue of $8.30B (+6.8%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.